Regional Anesthesia and Cancer Recurrence in Patients with Late-Stage Cancer: A Systematic Review and Meta-Analysis
Introduction
Cancer remains a leading cause of mortality globally, with disease stage at diagnosis serving as a critical determinant of prognosis and treatment strategy. Emerging preclinical and clinical studies have explored the potential role of anesthetic techniques in modulating cancer recurrence and metastasis. Regional anesthesia, through its proposed anti-inflammatory effects and attenuation of surgical stress responses, has been hypothesized to reduce immunosuppression and tumor-promoting signaling compared to general anesthesia. However, existing systematic reviews have reported conflicting results, largely due to heterogeneity in patient populations, particularly regarding cancer stage. Late-stage cancers, characterized by advanced local invasion or metastasis, represent a subgroup with heightened susceptibility to recurrence and may derive differential benefits from anesthetic interventions. This systematic review and meta-analysis aimed to evaluate the effect of regional anesthesia on recurrence-free survival (RFS) and overall survival (OS) in patients with late-stage cancers.
Methods
A comprehensive search of Medline, Embase, Cochrane Library, and ClinicalTrials.gov was conducted from inception to September 2020. Randomized controlled trials (RCTs) and cohort studies comparing regional anesthesia (with or without general anesthesia) or epidural analgesia to general anesthesia alone in late-stage cancer patients were included. Late-stage disease was defined according to the American Joint Committee on Cancer (AJCC) Staging Manual, 8th edition, encompassing stages III–IV for solid tumors. Studies were excluded if fewer than 25% of participants had late-stage disease.
Data extraction included study design, patient demographics, cancer type, anesthetic interventions, and survival outcomes. Hazard ratios (HRs) for RFS and OS were pooled using random-effects models. Heterogeneity was quantified via the I² statistic. Risk of bias was assessed using the Cochrane tool for RCTs and the Newcastle-Ottawa Scale for cohort studies. Subgroup analyses were predefined by study design, cancer type, anesthetic technique, follow-up duration, and confounder adjustment methods. Sensitivity analyses included studies regardless of cancer stage.
Results
Study Characteristics
The search identified 37 studies (3 RCTs, 34 cohort studies) involving 64,691 patients. Median patient age was 67.5 years, with 61.4% male. Cancer types included colorectal (19.4%), ovarian (16.1%), upper gastrointestinal (12.9%), and prostate (9.7%). Regional anesthesia techniques comprised epidural (70.9%), spinal (12.9%), and local anesthesia (16.1%). Comparators were general anesthesia (41.9%) or non-epidural analgesia (58.1%). Median follow-up was 5.3 years.
Risk of Bias
RCTs demonstrated low bias risk, with adequate randomization and outcome reporting. Cohort studies scored a mean of 6/9 on the Newcastle-Ottawa Scale, with limitations in representativeness of exposed cohorts.
Meta-Analysis Outcomes
Recurrence-Free Survival (RFS)
Pooled analysis of 31 studies (28 cohort, 3 RCTs) showed a modest reduction in recurrence risk with regional anesthesia (HR = 0.88, 95% CI: 0.79–0.97, P = 0.013, I² = 70%). However, subgroup analysis of RCTs (n = 3) revealed no significant benefit (HR = 1.12, 95% CI: 0.58–2.18, P = 0.729, I² = 76%). Observational studies alone favored regional anesthesia (HR = 0.87, 95% CI: 0.78–0.96, P = 0.008).
Overall Survival (OS)
Thirty studies (28 cohort, 2 RCTs) evaluated OS. Overall, regional anesthesia was associated with a survival benefit (HR = 0.88, 95% CI: 0.79–0.98, P = 0.022, I² = 79%). RCTs again showed no significant effect (HR = 0.86, 95% CI: 0.63–1.18, P = 0.345).
Subgroup Analyses
- Cancer Type: Greatest RFS benefits were observed in breast cancer (HR = 0.21, 95% CI: 0.06–0.72) and laryngeal/hypopharyngeal cancer (HR = 0.49, 95% CI: 0.25–0.96). No significant effects were noted in prostate or ovarian cancers.
- Anesthetic Technique: Epidural anesthesia/analgesia (HR = 0.87, 95% CI: 0.73–1.03) and spinal/local anesthesia (HR = 0.88, 95% CI: 0.77–1.01) showed comparable trends.
- Study Design: Retrospective cohorts favored regional anesthesia (HR = 0.85, 95% CI: 0.75–0.96), whereas prospective cohorts showed no effect (HR = 1.00, 95% CI: 0.89–1.13).
- Confounder Adjustment: Propensity score-adjusted studies demonstrated stronger protective effects (HR = 0.78, 95% CI: 0.67–0.90) compared to multivariable regression-adjusted studies (HR = 0.90, 95% CI: 0.77–1.04).
Sensitivity Analysis
Including all stages of cancer (n = 53 studies for RFS, n = 42 for OS) attenuated but maintained the significance of regional anesthesia benefits (RFS HR = 0.89, 95% CI: 0.82–0.97; OS HR = 0.89, 95% CI: 0.82–0.97).
Discussion
This meta-analysis highlights a discrepancy between observational studies and RCTs in assessing regional anesthesia’s impact on cancer outcomes. Observational data suggest a 12–13% reduction in recurrence and mortality risks, whereas RCTs, though limited in power and number, show no significant effects. This divergence may stem from residual confounding in cohort studies, such as unmeasured tumor biology variables or selection bias toward healthier patients receiving regional techniques.
Biological plausibility for regional anesthesia benefits includes reduced opioid use, attenuation of surgical stress responses, and direct anti-tumor effects of local anesthetics. Preclinical studies demonstrate that volatile anesthetics promote pro-metastatic gene expression, while local anesthetics inhibit cancer cell proliferation and migration. However, clinical translation remains uncertain, particularly in advanced cancers with established micrometastases.
The stage-specific analysis underscores the importance of patient stratification. Late-stage cancers exhibit aggressive biology and higher recurrence rates, potentially masking subtle intervention effects. Conversely, early-stage tumors may lack sufficient metastatic potential for anesthetic modulation to manifest clinically. Subgroup findings in breast and aerodigestive cancers suggest organ-specific mechanistic interactions warranting further investigation.
Limitations
Key limitations include heterogeneity in anesthetic protocols, cancer types, and staging systems. Only three RCTs focused on late-stage cancers, all secondary analyses of trials designed for other endpoints. Observational studies predominantly relied on administrative databases lacking granularity in tumor characteristics, adjuvant therapies, and recurrence monitoring.
Conclusions
Current evidence does not conclusively support regional anesthesia as a strategy to reduce recurrence or improve survival in late-stage cancers. While observational data signal potential benefits, RCTs remain underpowered and inconclusive. Clinical decisions should prioritize established oncologic principles over anesthetic modality. Future research requires large, pragmatic RCTs targeting late-stage populations, standardized anesthetic protocols, and integration of biomarker assessments to elucidate mechanistic pathways.
doi.org/10.1097/CM9.0000000000001676
Was this helpful?
0 / 0